Zepzelca (lurbinectedin) given US accelerated approval for treatment of adults with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy

Approval is based on Phase II study (n=105) which showed that in patients with relapsed SCLC, lurbinectedin (an RNA polymerase II inhibitor) demonstrated an overall response rate of 35% and a median duration of response of 5.3 months. UK developmental status is unknown.